Use of Everolimus After Multivisceral Transplantation: A Report of Two Cases
Recommended Citation
Rao B, Segovia MC, Kazimi M, Parekh R, Raoufi M, and Jafri SM. Use of everolimus after multivisceral transplantation: A report of two cases. Transplant Proc 2016; 48(2):485-488.
Document Type
Article
Publication Date
3-1-2016
Publication Title
Transplantation proceedings
Abstract
Inhibitors of mechanistic target of rapamycin are used in solid organ transplant procedures to avoid calcineurin inhibitor complications, including nephrotoxicity and malignancy. We present 2 cases of multivisceral transplantation for neuroendocrine tumor (NET) for which everolimus was implemented for its potential to prevent NET recurrence as well as preserve renal function. The first case was complicated by NET recurrence in the liver before initiation of everolimus. After initiation of everolimus, the patient developed a ventral hernia and elevated aminotransferase levels with nonspecific biopsy findings. The second case was complicated by cytomegalovirus infection with elevated everolimus trough levels as well as acute cellular rejection. Everolimus was reinitiated in both cases in addition to decreasing the dosage of tacrolimus, and there were no further complications. Everolimus was beneficial in stabilizing renal function in both patients and has the theoretical potential to prevent recurrence of NET.
Medical Subject Headings
Adult; Calcineurin Inhibitors; Everolimus; Female; Gastrointestinal Neoplasms; Graft Rejection; Humans; Immunosuppressive Agents; Intestines; Male; Middle Aged; Neoplasm Recurrence, Local; Neuroendocrine Tumors; Tacrolimus
PubMed ID
27109983
Volume
48
Issue
2
First Page
485
Last Page
488
